USPOULTRY and the USPOULTRY Foundation have announced the completion of a funded research project at the Ohio Agricultural Research and Development Center in Wooster, in which researchers looked at the role of vitamin D in fighting coccidiosis in turkeys. The research project has been designated as the Virgil H. Cooper Turkey Fund 2014 award and is part of the association’s comprehensive research program encompassing all phases of poultry and egg production and processing. A brief summary of the completed project is shown below. A complete report, along with information on other association research, may be obtained by going to www.uspoultry.org.
The project summary is as follows:
Project #689: 25-OH Cholecalciferol (HyD) Supplementation to Improve Anti-Coccidial Defense in Turkeys
(Dr. Ramesh Selvaraj, Ohio Agriculture Research and Development Center)
Dr. Selvaraj and colleagues found that supplementation of turkey feed with increased levels of a form of vitamin D, 25-OH cholecalciferol, improved body weight gain and decreased the fecal shedding of coccidial oocysts following coccidia challenge. This novel approach to controlling coccidiosis may prove useful for production programs which rely less on the use of anticoccidial compounds.
For a detailed summary, click here.
Showing posts with label coccidiosis. Show all posts
Showing posts with label coccidiosis. Show all posts
Wednesday, November 18, 2015
Monday, December 15, 2014
Zoetis reintroduces Zoamix to help battle coccidiosis
Zoetis Inc. has reintroduced Zoamix (zoalene), a versatile synthetic anticoccidial for the prevention and control of coccidiosis in broilers and turkeys.
“The U.S. poultry industry loses an estimated $600 million a year to coccidiosis, so the return of Zoamix could not be coming at a better time,” said Don Waldrip, DVM, DACPV, a senior technical services veterinarian with Zoetis.
He noted that U.S. poultry producers have not seen a new in-feed anticoccidial in 15 years, and concerns remain about existing products becoming less effective over time. “Having one more anticoccidial to use in a rotation program — especially one like Zoamix, which has a unique chemical structure — could help preserve the efficacy of other coccidiosis medications,” Waldrip said.
Versatile product
Zoamix is a Type A medicated article that can be used safely year-round with no withdrawal. Because it is a synthetic compound, Zoamix is compatible with antibiotic-free or conventional production systems. As with all in-feed anticoccidials, Zoetis recommends resting the medication periodically to maintain good efficacy.
According to Waldrip, Zoamix is unique in that it’s a synthetic compound but works similarly to an ionophore by allowing some cycling of Eimeria, the parasite that causes coccidiosis. “That cycling, commonly called leakage by poultry producers and veterinarians, allows the development of natural immunity against the disease,” the veterinarian explained.
Waldrip said the arrival of Zoamix would further strengthen Rotecc Coccidiosis Management, a science-based initiative Zoetis launched earlier this year to help poultry producers develop more strategic, cost-effective and sustainable programs for battling the costly parasitic disease.
More uses
In addition to preventing and controlling coccidiosis in broilers and turkeys, Zoamix can be used for the development of active immunity against coccidiosis in replacement chickens. Zoamix is also approved for use in combination with BMD (bacitracin methylene disalicylate), a feed medication used to manage necrotic enteritis in chickens and transmissible enteritis in turkeys.
Formerly produced by Alpharma, Zoamix was used by the U.S. broiler and turkey industries for more than four decades before leaving the market in 2005 due to shortage of a key ingredient. Zoetis later acquired the product, saw the poultry industry’s need for Zoamix, and worked with suppliers to resolve supply issues and relaunch the product.
Monday, August 4, 2014
Breakthrough in coccidiosis research at Royal Veterinary College
Biological researchers at the University of London’s Royal Veterinary College (RVC) are a step closer to finding a new cost-effective vaccine for the intestinal disease, coccidiosis. The disease, caused by protozoan parasites of the genus Eimeria, affects chickens’ intestines and if not controlled has extremely high mortality rates.
Domestic chickens can be infected by seven species of Eimeria, each colonizing a preferred region of the intestine and causing symptoms of differing severity. In a decade-long collaborative research project, biologists at the RVC have helped produce full genome sequences of all seven of these species.
This is major breakthrough for the poultry production industry in its fight against coccidiosis, which puts the global economic cost of infection at around GBP1.8 billion (US$3.06 billion). This is mainly due to production losses combined with costs of prevention and treatment.
The research is being published in the academic journal Genome Research and is funded by the Biotechnology and Biological Sciences Research Council.
Coccidiosis affects all livestock but is particularly hurtful to poultry because of the high density that chickens can be housed in during the production process. Eimeria species that cause coccidiosis have a direct fecal-oral life cycle that is ideal for spreading rapidly through susceptible hosts when housed in close quarters.
These parasites are also particularly devastating because they survive for long periods in environments such as feces and litter. This means most chicken flocks in the world are exposed, with many inevitably becoming infected. Drugs are commonly used to control the parasites, but resistance evolves rapidly and there is a continuing need to develop new, effective control of disease.
Professor Fiona Tomley, RVC head of pathology and pathogen biology, and Dr. Damer Blacke, RVC senior lecturer in parasitology, are co-authors of the research, which is being published in the academic journal, Genome Research.
“Understanding the genetic code of Eimeria parasites will help in the race to develop new therapies for coccidiosis,” said Tomley. “With poultry production expansion predicted to continue for at least the next 30 years, and with Africa and Asia accounting for most of this growth, developing a new generation of cheap effective vaccines against coccidiosis will be a major contribution to global food security.”
Thursday, January 30, 2014
Zoetis introduces Rotecc Coccidiosis-Management Initiative
Zoetis Inc. introduced Rotecc Coccidiosis Management, a new, science-based initiative to help poultry producers worldwide develop more strategic, cost-effective and sustainable programs for battling the costly parasitic disease.
"Overall, the poultry industry has done a commendable job managing coccidiosis. But clearly, when you look at billions of dollars in losses associated with the disease, there is still lots of room for improvement," Mark LaVorgna, Ph.D., a nutritionist and global technical services director for the company, said at a news conference in Atlanta before the 2014 International Production and Processing Expo.
Rotecc begins with a consultation by a Zoetis representative, who reviews a poultry operation's past and current programs, necropsy data and results from anticoccidial sensitivity testing, as well as seasonal preferences for product usage, production goals and management practices. Other variables such as feed costs and meat prices also are considered.
Rotecc is built on best practices widely accepted by the poultry science community for coccidiosis management. Specifically, this includes not using the same in-feed anticoccidial for too long, rotating among products from different classes, resting each product and using a synthetic anticoccidial once yearly to clean up lingering coccidia and help reduce infection pressure.
Don Waldrip, D.V.M., senior technical services veterinarian for the company, with years of production experience, said poultry producers would benefit from thinking longer term - perhaps even 24 months ahead - when developing their coccidiosis-management programs.
To support Rotecc, Zoetis is developing several digital tools to help producers and veterinarians tailor a long-term program to suit their individual needs. These include the Rotecc Program Advisor, an iPad app that initially will be available in the U.S., and a Rotecc Calculator, which will run on the iPad and Windows operating systems. It will be used to help determine the most cost-effective anticoccidials for each producer's rotation plan while adhering to best practices for rotation.
"Overall, the poultry industry has done a commendable job managing coccidiosis. But clearly, when you look at billions of dollars in losses associated with the disease, there is still lots of room for improvement," Mark LaVorgna, Ph.D., a nutritionist and global technical services director for the company, said at a news conference in Atlanta before the 2014 International Production and Processing Expo.
Rotecc begins with a consultation by a Zoetis representative, who reviews a poultry operation's past and current programs, necropsy data and results from anticoccidial sensitivity testing, as well as seasonal preferences for product usage, production goals and management practices. Other variables such as feed costs and meat prices also are considered.
Rotecc is built on best practices widely accepted by the poultry science community for coccidiosis management. Specifically, this includes not using the same in-feed anticoccidial for too long, rotating among products from different classes, resting each product and using a synthetic anticoccidial once yearly to clean up lingering coccidia and help reduce infection pressure.
Don Waldrip, D.V.M., senior technical services veterinarian for the company, with years of production experience, said poultry producers would benefit from thinking longer term - perhaps even 24 months ahead - when developing their coccidiosis-management programs.
To support Rotecc, Zoetis is developing several digital tools to help producers and veterinarians tailor a long-term program to suit their individual needs. These include the Rotecc Program Advisor, an iPad app that initially will be available in the U.S., and a Rotecc Calculator, which will run on the iPad and Windows operating systems. It will be used to help determine the most cost-effective anticoccidials for each producer's rotation plan while adhering to best practices for rotation.
Tuesday, December 24, 2013
Coccidiosis can play a role in Salmonella control
Coccidiosis control continues to be a top concern for broiler veterinarians in the U.S., in spite of the estimated $90 million per year spent on prevention, according to Dr. Greg Mathis, president and researcher, Southern Poultry Research, Inc. Mathis, speaking at WATT Global Media's "Coccidiosis vaccination: A new approach to Salmonella control" webinar, said that broilers vaccinated for coccidiosis have lower lesion scores than do birds treated with either chemical coccidiostats or ionophores.
Mathis said that there are nine species of coccidia that impact broilers, with E. acervulina, E. tenella and E. maxima being the most prevalent. E. tenella is primarily found in the ceca and it is the species of coccidia that seems to affect Salmonella levels in broilers the most. Mathis said that better control of E. tenella may lower Salmonella incidence in a flock at time of market.
Impact of vaccination
Dr. Charles Hofacre, researcher, poultry diagnostic research center, University of Georgia, said that coccidiosis vaccination is regaining popularity with broiler companies for a number of factors. Resistance of coccidia populations in broiler houses to both chemical coccidiostats and ionophores continues to be a growing problem with no new drugs introduced in the last few decades. Hofacre said that vaccinating for coccidiosis reestablishes populations of susceptible strains of coccidia on broiler farms. Finally, he said that the growth of the antibiotic-free movement among some consumers has also increased use of coccidiosis vaccines.
Research has shown that coccidiosis breaks in broilers associated with E. necatrix and E. tenella are associated with increases in Salmonella colonization in the bird. Hofacre said the E. necatrix control in breeders plays a role in helping to keeps Salmonella loads on chicks low, but that E. tenella control is of more importance for controlling Salmonella colonization in the broiler house.
Coccidiosis control and Salmonella
Hofacre reported on a challenge study where birds were raised on built up litter and where either vaccinated for coccidiosis or treated with an ionophore coccidiostat, Salinomycin. In addition to being raised on built-up litter, half of the birds in this study were challenged with Salmonella Heidelberg. Salmonella Heidelberg levels were numerically lower in the drag swabs of the pens with vaccinated birds. The vaccinated broilers had lower cecal Salmonella counts than did the Salinomycin treated birds.
"Coccidia vaccine in this study numerically reduced environmental load, prevalence and cecal number of Salmonella Heidelberg," said Hofacre. Coccidiosis control alone won't solve Salmonella problems for a broiler producer, but it can contribute to the solution. "We reduce Salmonella not by silver bullets but by multiple methods that build to success."
Mathis said that there are nine species of coccidia that impact broilers, with E. acervulina, E. tenella and E. maxima being the most prevalent. E. tenella is primarily found in the ceca and it is the species of coccidia that seems to affect Salmonella levels in broilers the most. Mathis said that better control of E. tenella may lower Salmonella incidence in a flock at time of market.
Impact of vaccination
Dr. Charles Hofacre, researcher, poultry diagnostic research center, University of Georgia, said that coccidiosis vaccination is regaining popularity with broiler companies for a number of factors. Resistance of coccidia populations in broiler houses to both chemical coccidiostats and ionophores continues to be a growing problem with no new drugs introduced in the last few decades. Hofacre said that vaccinating for coccidiosis reestablishes populations of susceptible strains of coccidia on broiler farms. Finally, he said that the growth of the antibiotic-free movement among some consumers has also increased use of coccidiosis vaccines.
Research has shown that coccidiosis breaks in broilers associated with E. necatrix and E. tenella are associated with increases in Salmonella colonization in the bird. Hofacre said the E. necatrix control in breeders plays a role in helping to keeps Salmonella loads on chicks low, but that E. tenella control is of more importance for controlling Salmonella colonization in the broiler house.
Coccidiosis control and Salmonella
Hofacre reported on a challenge study where birds were raised on built up litter and where either vaccinated for coccidiosis or treated with an ionophore coccidiostat, Salinomycin. In addition to being raised on built-up litter, half of the birds in this study were challenged with Salmonella Heidelberg. Salmonella Heidelberg levels were numerically lower in the drag swabs of the pens with vaccinated birds. The vaccinated broilers had lower cecal Salmonella counts than did the Salinomycin treated birds.
"Coccidia vaccine in this study numerically reduced environmental load, prevalence and cecal number of Salmonella Heidelberg," said Hofacre. Coccidiosis control alone won't solve Salmonella problems for a broiler producer, but it can contribute to the solution. "We reduce Salmonella not by silver bullets but by multiple methods that build to success."
Friday, November 1, 2013
Register for free webinar: 'Coccidiosis Vaccination: A New Approach to Salmonella Control'
The free webinar, "Coccidiosis Vaccination: A New Approach to Salmonella Control," will be presented Thursday, December 19.
Register for the free webinar, Coccidiosis Vaccination: A New Approach to Salmonella Control, which will be held Thursday, December 19 at 9 a.m. CT.
A sound coccidiosis vaccination program helps develop an early solid immunity to the intestinal parasite Eimeria. The importance of good intestinal health is important in reducing Salmonella colonization and shedding in the chicken house.
What you'll learn:
-The basics needed for a good vaccination program.
-The relationship between intestinal health and Salmonella
-How to develop a good coccidiosis and Salmonella control program
The speakers for this webinar are Dr. Charles L. Hofacre, director clinical services, Poultry Diagnostic Research Center; and Dr. Greg Mathis, Southern Poultry Research Inc.
This webinar is sponsored by Merck Animal Health and presented by WATT Global Media.
Tuesday, August 6, 2013
Feed ingredient may manage coccidiosis in broilers, according to study
Independent studies found that Original XPC many help manage coccidiosis in broilers. Original XPC is a feed ingredient from Diamond V, a fermentation product manufacturer.
The effects of Original XPC and a coccidiostat (Salinomycin) were investigated individually and in combination at Southern Poultry Research during a coccidiosis challenge in broiler chickens. A total of 320 test birds were housed and lesion scores were conducted. Male broilers (Cobb X Cobb) were used from zero to 27 days of age. All birds received vaccinations at the hatchery for Marek's Disease (HVT:SB-1) and birds were weighed at zero, 21 and 27 days of age. Feed consumption was measured at 21 days and 27 days. The study included five treatments with eight birds per cage and eight replicate cages per treatment. Test articles were added to the feed of each treatment.
All birds except the negative controls were challenged orally with a coccidia inoculum at 21 days. The challenge dose per bird was designed to be much greater than a routine field challenge and to produce approximately 3.0 lesion scores for each species in the infected, non-medicated control group.
At 27 days, all birds from each cage were lesion scored. The upper, middle and cecal regions of the intestine were scored, using the system of Johnson and Reid where 0 is normal and 1, 2, 3, or 4 indicate increasing severity of infection.
E. acervulina coccidia lesions sores were reduced in the upper gastrointestinal tract when Original XPC was included in the feed. Salinomycin inclusion further reduced lesions compared to the non-medicated, infected group. E. maxima lesion scores in the mid gut were also significantly reduced with the addition of Original XPC to the diets, and the response was equivalent to that of Salinomycin and to the combination of products. Cecal lesions reflecting E. tenella were also significantly reduced when feeding Original XPC, and an even greater response was observed when Salinomycin was included.
Body weight gain during the coccidiosis infection was severely affected in the non-medicated, infected group. Adding Original XPC to the feed significantly improved body weight gain, and Salinomycin produced even greater gain. The combination of Original XPC and Salinomycin provided the greatest weight gain among the infected groups.
The treatment response for feed conversion ratio was similar to body weight gains. Significant improvement was seen both with Original XPC and Salinomycin. Combining Original XPC and Salinomycin resulted in feed conversion similar to that of non-infected controls.
Previous research had suggested that the metabolites in Diamond V Original XPC empower the bird's immune system by strengthening the instinctive immune response and supporting adaptive immunity within the gastrointestinal tract. In addition, chemical signals help suppress the inflammatory response during a challenge, and metabolites in Original XPC increase antibody production to commercial vaccines.
Previous work also demonstrated that feeding Original XPC can reduce the incidence and severity of intestinal lesions when birds are challenged with coccidiosis. Further evidence of reduced coccidiosis stress from feeding Original XPC is the improved body weight gain and feed conversion when birds are fed Original XPC during a coccidia challenge.
The effects of Original XPC and a coccidiostat (Salinomycin) were investigated individually and in combination at Southern Poultry Research during a coccidiosis challenge in broiler chickens. A total of 320 test birds were housed and lesion scores were conducted. Male broilers (Cobb X Cobb) were used from zero to 27 days of age. All birds received vaccinations at the hatchery for Marek's Disease (HVT:SB-1) and birds were weighed at zero, 21 and 27 days of age. Feed consumption was measured at 21 days and 27 days. The study included five treatments with eight birds per cage and eight replicate cages per treatment. Test articles were added to the feed of each treatment.
All birds except the negative controls were challenged orally with a coccidia inoculum at 21 days. The challenge dose per bird was designed to be much greater than a routine field challenge and to produce approximately 3.0 lesion scores for each species in the infected, non-medicated control group.
At 27 days, all birds from each cage were lesion scored. The upper, middle and cecal regions of the intestine were scored, using the system of Johnson and Reid where 0 is normal and 1, 2, 3, or 4 indicate increasing severity of infection.
E. acervulina coccidia lesions sores were reduced in the upper gastrointestinal tract when Original XPC was included in the feed. Salinomycin inclusion further reduced lesions compared to the non-medicated, infected group. E. maxima lesion scores in the mid gut were also significantly reduced with the addition of Original XPC to the diets, and the response was equivalent to that of Salinomycin and to the combination of products. Cecal lesions reflecting E. tenella were also significantly reduced when feeding Original XPC, and an even greater response was observed when Salinomycin was included.
Body weight gain during the coccidiosis infection was severely affected in the non-medicated, infected group. Adding Original XPC to the feed significantly improved body weight gain, and Salinomycin produced even greater gain. The combination of Original XPC and Salinomycin provided the greatest weight gain among the infected groups.
The treatment response for feed conversion ratio was similar to body weight gains. Significant improvement was seen both with Original XPC and Salinomycin. Combining Original XPC and Salinomycin resulted in feed conversion similar to that of non-infected controls.
Previous research had suggested that the metabolites in Diamond V Original XPC empower the bird's immune system by strengthening the instinctive immune response and supporting adaptive immunity within the gastrointestinal tract. In addition, chemical signals help suppress the inflammatory response during a challenge, and metabolites in Original XPC increase antibody production to commercial vaccines.
Previous work also demonstrated that feeding Original XPC can reduce the incidence and severity of intestinal lesions when birds are challenged with coccidiosis. Further evidence of reduced coccidiosis stress from feeding Original XPC is the improved body weight gain and feed conversion when birds are fed Original XPC during a coccidia challenge.
Tuesday, April 16, 2013
Alternative method to manage coccidiosis proven in test
Scientific evaluation
of the different alternative solutions for coccidiosis
management in broilers has shown that Oilis allows the best European Performance Index during the
recovery period and optimum nutrients' assimilation.
Coccidiosis is a very common pathology in broiler houses actually controlled by antibiotic coccidiostatic products. Due to increase of microbes' resistance to antibiotics, the tendency now is to reduce their use in animal farming. Because of that, there is growing need for alternatives to those antibiotic products.
Coccidiosis is a very common pathology in broiler houses actually controlled by antibiotic coccidiostatic products. Due to increase of microbes' resistance to antibiotics, the tendency now is to reduce their use in animal farming. Because of that, there is growing need for alternatives to those antibiotic products.
In this context, the current study is aimed to compare the
efficiency of different non antibiotic products for broiler chickens affected by
coccidiosis.
Oilis, Neovia's natural
alternative solution for coccidiosis, has been tested among its competitors'
products on a specific challenge model developed by Neovia, where birds are
inoculated with three different strains of Eimeria species to generate clinical
coccidiosis The results of the study performed on 660-day old chicks are
synthetized on the following poster presented during 10th Poultry Research Days in France. They prove that Oilis
group obtained the best performances in general and especially during the
recovery period.
Furthermore, intestinal lesions in different part of intestinal
tract are reduced by Oilis allowing faster recovery and thus a better nutrients'
assimilation. This is also clearly illustrated by the significantly higher
plasmatic coloration obtained in the Oilis group.
To conclude, this trial demonstrates that Oilis is able to
limit the impact of coccidiosis in broiler chicken farms. Efficiency and mode of
actions of products proved to be very variable, confirming the necessity to
evaluate the different products on suitable targeted models.
In this context, Oilis allows the best European Performance
Index, especially in the recovery period and optimizes assimilation of
nutrients.
Monday, March 25, 2013
Poultry industry needs, consumer demand topics at Alltech symposium
- Epigenetics: The Role of Parental Nutrition in Shaping Offspring Health
- Eggs: The Perfect Nutrient in the Perfect Nutrient Delivery System
- Reimagining Nutrition Part 1: The Role of Solid State Fermentation to Reduce Diet Costs
- Coccidiosis Control: Confronting the Reality in an Era of Fewer Viable Options
- Gut Immunity and Homeostatis: How Intestinal Microflora Interacts with the Immune System and Disease
- Unlocking Genetic Potential with Natural Nutrition
- Mycotoxins: The Global Picture
- Crisis Management- How Will Your Firm Handle a Crisis?
- Branding Food: Is it Niche or Mainstream?
- Reimagining Nutrition: How Nutrigenomics is Revolutionizing How We Feed
- Is Truly Antibiotic-Free Animal Production Possible?
From problems with mycotoxins and coccidiosis, to opportunities with epigenetics and antibiotic-free programs, Alltech plans to address a plate full of topics that affect the poultry industry, from the hatchery to the dining room, at GLIMPSE 2020: the 29th Annual Alltech International Symposium in Lexington, Ky., May 19-22.
New in 2013, Alltech International Symposium delegates will have the opportunity to select breakout session tracks. These tracks, as opposed to traditional species or subject breakouts, will offer attendees a more holistic experience in which they take part in discussions ranging from algae and agriculture's carbon footprint to nutrition and marketing.
"With daily blogs, tweets and posts demanding cage free, farm fresh and organic products, we need to listen to what consumers are saying, determine the best route to market and meet their expectations. At this year's Symposium, we will look at opportunities to improve meat quality and the customer experience by further investigating parameters such as tenderness, drip loss, cooking loss and shelf life," said Paulo Rigolin, chairperson for the poultry antibiotic-free track at Symposium. "It is more critical than ever to shift from the mindset of 'just being in the poultry business' to recognizing our role in a food industry that must feed an additional billion people by 2020."
Poultry-focused breakout session tracks include:
Attendees are encouraged to register early as space is limited. Of the nearly 3,000 international delegates who attended the 2012 Alltech International Symposium, 97 percent indicated that they plan to attend again.
For more information, or to request an invitation, contact a local Alltech representative, visit www.alltech.com/symposium or email symposium@alltech.com.
New in 2013, Alltech International Symposium delegates will have the opportunity to select breakout session tracks. These tracks, as opposed to traditional species or subject breakouts, will offer attendees a more holistic experience in which they take part in discussions ranging from algae and agriculture's carbon footprint to nutrition and marketing.
"With daily blogs, tweets and posts demanding cage free, farm fresh and organic products, we need to listen to what consumers are saying, determine the best route to market and meet their expectations. At this year's Symposium, we will look at opportunities to improve meat quality and the customer experience by further investigating parameters such as tenderness, drip loss, cooking loss and shelf life," said Paulo Rigolin, chairperson for the poultry antibiotic-free track at Symposium. "It is more critical than ever to shift from the mindset of 'just being in the poultry business' to recognizing our role in a food industry that must feed an additional billion people by 2020."
Poultry-focused breakout session tracks include:
Attendees are encouraged to register early as space is limited. Of the nearly 3,000 international delegates who attended the 2012 Alltech International Symposium, 97 percent indicated that they plan to attend again.
For more information, or to request an invitation, contact a local Alltech representative, visit www.alltech.com/symposium or email symposium@alltech.com.
Friday, February 15, 2013
Ceva rapid growth expected to continue in 2013
Ceva Holdings, Inc. affirmed its continued growth in 2013 for the North America market following the financial reporting results of its parent company, Ceva Santé Animale. The company completed its consolidation of its North America headquarters operations to the Lenexa, Kan., campus in late fall 2012. The move expanded the company workforce and has already resulted in better synergies to serve customers more efficiently for both its Ceva Animal Health and Ceva Biomune subsidiaries.
In 2012, Vectra parasiticide sales grew 34.5 percent in the US. Feliway and Adaptil continued to drive expansion of the behavior segment growing 30.4 percent. The company also entered the equine market in the United States with the launch of Altresyn (altrenogest).
In the avian market, Ceva captured the number two market position in 2012 after the successful conclusion of Ceva’s integration of Vetech Laboratories, a Canadian poultry vaccine manufacturer that markets live vaccines against coccidiosis. This allowed Ceva to add Vetech’s live coccidiosis vaccine Immucox T to the portfolio in the highly competitive United States market, expanding the poultry vaccine range from respiratory to also include intestinal health.
“We are coming off a very strong year and believe Ceva will continue growth with an outstanding team in place, with great existing and new products, and with continued financial support and commitment to the veterinary profession, “said Craig Wallace, Chief Executive Officer of Ceva Holdings, Inc.
Demonstrating Ceva’s commitment to grow its management team, Dr. Karen Padgett joined Ceva January 1 as Chief Operating Officer of the Ceva Animal Health Companion Animal Group. Padgett is a 28-year veteran of the animal health industry, most of which has been spent at Hill’s Pet Nutrition, a division of Colgate-Palmolive.
Upon being named to the position, Dr. Padgett said, “Ceva is a global company that is rapidly growing, but shows true commitment to the veterinary profession. I am thrilled to join the organization to lead a dynamic team and continue to contribute to the veterinary profession in a meaningful way. It’s a tremendous opportunity.”
The company plans to not only continue to market its products aggressively, but help educate pet owners to drive traffic to veterinary clinics. The Vectra brand will be supported in 2013 by a multi-media advertising campaign which includes television advertising and a "first dose free” coupon program.
The Feliway line will be extended with the introduction of new Feliway Wipes at the Western Veterinary Conference. Both Adaptil and Feliway will be supported by a major nationwide Behavior Advocate Program and veterinary exclusive trial generating consumer programs. In addition, the successful public relations bus tour will be expanded. The tour is aimed at increasing awareness that there are solutions to help keep pets from being put down due to unwanted behavior issues.
Ceva Animal Health has increased its visibility in the veterinary profession by joining in the celebration of the American Veterinary Medical Association’s 150th Anniversary as a sponsor. The company is also a sponsor of the One Health, One World initiative, is an inaugural sponsor of the American Association of Feline Practitioner’s Cat Practice initiative, and continues its commitment to educating veterinarians through conference CE and a new state veterinary medical association program.
Ceva Biomune’s $7 million renovation to its research and development facility in Lenexa announced in July 2012 is expected to be completed in June, 2013. The renovation will give the team 18,000 square feet of bio safety level 2 laboratory space and 15,000 square feet of office space. In May 2011, Ceva completed an $18 million expansion of its Biomune poultry vaccine production plant on the Ceva Biomune campus.
“Continued expansion of our research and manufacturing facilities is critical to meeting the needs of our domestic and global customers. We are on schedule to deliver on that investment and look forward to the opening of the renovated research and development facility,” said Daryl Pint, Chief Executive Officer of Ceva Biomune.
In 2012, Vectra parasiticide sales grew 34.5 percent in the US. Feliway and Adaptil continued to drive expansion of the behavior segment growing 30.4 percent. The company also entered the equine market in the United States with the launch of Altresyn (altrenogest).
In the avian market, Ceva captured the number two market position in 2012 after the successful conclusion of Ceva’s integration of Vetech Laboratories, a Canadian poultry vaccine manufacturer that markets live vaccines against coccidiosis. This allowed Ceva to add Vetech’s live coccidiosis vaccine Immucox T to the portfolio in the highly competitive United States market, expanding the poultry vaccine range from respiratory to also include intestinal health.
“We are coming off a very strong year and believe Ceva will continue growth with an outstanding team in place, with great existing and new products, and with continued financial support and commitment to the veterinary profession, “said Craig Wallace, Chief Executive Officer of Ceva Holdings, Inc.
Demonstrating Ceva’s commitment to grow its management team, Dr. Karen Padgett joined Ceva January 1 as Chief Operating Officer of the Ceva Animal Health Companion Animal Group. Padgett is a 28-year veteran of the animal health industry, most of which has been spent at Hill’s Pet Nutrition, a division of Colgate-Palmolive.
Upon being named to the position, Dr. Padgett said, “Ceva is a global company that is rapidly growing, but shows true commitment to the veterinary profession. I am thrilled to join the organization to lead a dynamic team and continue to contribute to the veterinary profession in a meaningful way. It’s a tremendous opportunity.”
The company plans to not only continue to market its products aggressively, but help educate pet owners to drive traffic to veterinary clinics. The Vectra brand will be supported in 2013 by a multi-media advertising campaign which includes television advertising and a "first dose free” coupon program.
The Feliway line will be extended with the introduction of new Feliway Wipes at the Western Veterinary Conference. Both Adaptil and Feliway will be supported by a major nationwide Behavior Advocate Program and veterinary exclusive trial generating consumer programs. In addition, the successful public relations bus tour will be expanded. The tour is aimed at increasing awareness that there are solutions to help keep pets from being put down due to unwanted behavior issues.
Ceva Animal Health has increased its visibility in the veterinary profession by joining in the celebration of the American Veterinary Medical Association’s 150th Anniversary as a sponsor. The company is also a sponsor of the One Health, One World initiative, is an inaugural sponsor of the American Association of Feline Practitioner’s Cat Practice initiative, and continues its commitment to educating veterinarians through conference CE and a new state veterinary medical association program.
Ceva Biomune’s $7 million renovation to its research and development facility in Lenexa announced in July 2012 is expected to be completed in June, 2013. The renovation will give the team 18,000 square feet of bio safety level 2 laboratory space and 15,000 square feet of office space. In May 2011, Ceva completed an $18 million expansion of its Biomune poultry vaccine production plant on the Ceva Biomune campus.
“Continued expansion of our research and manufacturing facilities is critical to meeting the needs of our domestic and global customers. We are on schedule to deliver on that investment and look forward to the opening of the renovated research and development facility,” said Daryl Pint, Chief Executive Officer of Ceva Biomune.
Subscribe to:
Posts (Atom)
